BrainsWay Further Expands Access to Deep TMS in Asia Pacific Region

Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS in Taiwan

BURLINGTON, Mass. and JERUSALEM, Aug. 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in Taiwan. BrainsWay’s most recent delivery of systems is expected to bring its installed base in this important Asia Pacific country to 16 Deep TMS systems, including another 5 systems planned for installation before the end of the current quarter.

“More than 260 million people in the world are affected by depression, with nearly one-third receiving inadequate relief from first-line pharmaceutical treatments. BrainsWay’s mission is to improve health and transform lives, and this means increasing access to Deep TMS globally, especially for treatment-resistant patients who desperately need help,” said Hadar Levy, Chief Executive Officer of BrainsWay. “Our expansion in Taiwan is an important step in ensuring that depression patients, regardless of geography, have access to the care they need.”

BrainsWay has partnered with Unison Healthcare Group to strategically enhance access and awareness of Deep TMS in the Taiwanese market. Unison has been working closely with key hospitals, clinics, and thought leaders to ensure no patient suffers needlessly from a condition for which Deep TMS can provide a viable and efficacious treatment option. These efforts have resulted in an accelerated adoption of the technology and treatment across the country.

“We are proud to partner with BrainsWay in bringing this important noninvasive treatment to the people of Taiwan who desperately need options to address their treatment-resistant major depressive disorder,” said Mr. Shih Wei-Lun, Unison Healthcare Group’s Chief Executive Officer. “There are approximately 1.5 million patients suffering from depression in Taiwan. For those individuals that are resistant to other therapies, Deep TMS represents a unique non-drug option to alleviate the symptoms of this serious mental health condition.”